GAMMA KNIFE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Gamma Knife Market Analysis & Forecast: 2026-2033

Gamma Knife Market is estimated to be valued at USD 280.49 Bn in 2026 and is expected to reach USD 410.74 Bn in 2033, exhibiting a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.

Key Takeaways

• According to Indication, The Brain Metastasis Category is anticipated to account for the largest share of 36.2% the Gamma Knife market in 2026.
• According to region, North America also holds the largest market share of 33.5% for Gamma Knife market growth by 2026.

Market Overview

Gamma Knife Market is set for sustained growth which is driven by the need for minimally invasive, precise neurosurgical treatments, technological innovation, and expanding healthcare access especially in emerging markets. The Gamma Knife Market Size fuels the demand as the technology delivers a single, finely focused, high dose of radiation to the target area which causes minimal or no damage to surrounding healthy tissue.

For instance, in June 2024, Fortis Memorial Research Institute launched South Asia's first Gamma Knife Esprit, marking a significant advancement in the non-surgical treatment of brain tumours. This latest version of the Leksell Gamma Knife enhances the therapeutic options for both malignant and benign brain tumours and other brain abnormalities.

Current Events and Its Impact on the Gamma Knife Market

Pipeline Analysis

Leading companies such as Elekta, Varian Medical Systems, and others are investing in next-generation Gamma Knife systems with improved imaging, targeting accuracy, and patient comfort. New models are increasingly integrated with advanced MRI and CT imaging, enabling more precise treatment planning and real-time monitoring.

Enhanced software platforms are being developed for better dose planning, workflow efficiency, and data analytics, supporting personalized radiosurgery regimens. While brain metastases and arteriovenous malformations (AVMs) remain core indications, the pipeline is expanding to include functional disorders (e.g., trigeminal neuralgia), vascular malformations, and ocular diseases.

Patent Landscape

• The patent landscape for the Gamma Knife market is shaped by continuous innovation in non-invasive radiosurgery technologies, with a focus on improving precision, safety, and clinical outcomes for neurological disorders and brain tumors.
• Elekta AB is the dominant player, holding an extensive patent portfolio covering critical innovations in Gamma Knife technology, including collimator designs, dose sculpting, and advanced imaging integration38. Elekta’s patents underpin much of the technological advancement in the market, supporting its leading position and product line expansions.
• There is a clear trend toward patents that enable higher precision, automation, and user-friendly interfaces, reflecting the market’s demand for improved patient outcomes and operational efficiency.

Reimbursement Scenario

The U.S. Centers for Medicare & Medicaid Services (CMS) and other comparable organizations throughout the world have a significant influence on the reimbursement picture for the Gamma Knife market.  In the US, certain procedure codes are usually used to cover Gamma Knife operations under the Hospital Outpatient Prospective Payment System (HOPPS).  Reimbursement rates have varied in the past; for instance, CMS raised Gamma Knife reimbursement by 28% in 2006 over the prior year, indicating that its therapeutic value was recognized.

Prescribers’ preference

As Gamma Knife radiosurgery is non-invasive, highly precise, and has good patient outcomes, prescribers particularly neurosurgeons, oncologists, and radiation specialists—show a strong and growing preference for it.  Due to its ability to deliver gamma radiation precisely, minimizing damage to surrounding healthy tissue and drastically cutting down on recovery time when compared to open surgery, the Gamma Knife is frequently used to treat brain tumors, arteriovenous malformations (AVMs), and functional brain disorders like trigeminal neuralgia.

Segmentation Analysis

Gamma Knife Market Insights, by Indication

In terms of indication, the brain metastasis segment is expected to contribute largest share of the Gamma Knife market trends in 2026, as the increasing prevalence of brain metastases due in part to higher survival rates in primary cancers such as lung, breast, melanoma, and renal carcinoma which drives demand for effective minimally invasive treatments like Gamma Knife radiosurgery.   

For instance, in November 2024, In a significant milestone for neurosurgical innovation KIMS Hospital has unveiled its cutting-edge Gamma Knife Centre, bringing world-class, non-invasive brain treatment technology to Hyderabad. The advanced technology is especially effective in treating conditions such as brain metastasis arteriovenous malformations (AVMs), acoustic neuromas, pituitary tumors, and functional disorders like trigeminal neuralgia and epilepsy.

Gamma Knife Market Insights, by Application

In terms of application, the head segment is expected to contribute largest share of the Gamma Knife market trends in 2026, the technology allows for the delivery of high dose radiation with exceptional accuracy, minimizing exposure to healthy brain tissue and reducing side effects.

Gamma Knife Market Insights, by End User

In terms of end user, the hospital segment is expected to contribute largest share of the Gamma Knife market trends in 2026, as hospitals are often equipped with the necessary infrastructure and multidisciplinary teams required for Gamma Knife procedures which includes neusurgeons, radiation oncologists, and speacilaized nursing staff.

For instance, in May 2026, Kims Delighted to launch the Gamma Knife Centre – a cutting-edge, non-invasive radiosurgery facility for complex brain conditions. No surgical incision, no pain, no blood just precise treatment with focused radiation beams. Ideal for brain tumors & functional disorders like trigeminal neuralgia.

Regional Insights

North America Gamma Knife Market

Among regions, North America is estimated to hold a dominant position in the global gamma knife market over the forecast period. North America is estimated to hold 33.5% of the market share in 2026. The global gamma knife market is expected to witness significant growth in the coming years; driven increasing prevalence of neurological disorders is contributing to the growth of the gamma knife market in the North America region.

For instance, according to the American Neurological Association (ANA) in March 2021, neurological diseases affect around 100 billion people in the U.S. This significant number of patients with one neurological disorder is expected to increase the number of neurosurgeries in the U.S., thereby driving demand for gamma knife in the U.S.

Increasing prevalence of head and neck cancer in North America is also expected to boost demand gamma knife market in North America region. For instance, according to the American Society of Clinical Oncology (ASCO), in January 2021, head and neck cancer accounted for about 4% of all cancers in the United States. In 2020, an estimated 66,630 people (48,740 men and 17,890 women) had developed head and neck cancer, and also estimated that 14,620 deaths from head and neck cancer in 2020. Thus, this constantly increasing head and neck cancer will help in the growth of the market.

Asia Pacific Gamma Knife Market

The region is forecasted to have the highest growth rate globally, outpacing other markets due to increasing investments and demand. Rising incidence of cancer and neurological disorders, particularly brain tumors and vascular malformations, is fueling demand for Gamma Knife procedures. A large and aging population, especially in China and Japan, increases the patient pool requiring advanced neurosurgical interventions.

Gamma Knife Market In Europe

Key drivers for market expansion include increased use of Gamma Knife radiosurgery for treating brain tumors, epilepsy, vascular malformations, and other central nervous system conditions, as well as greater adoption in cancer surgical centers.    

Gamma Knife Market Dominating Countries

U.S Gamma Knife Market

This growth is driven by a high prevalence of neurological disorders and brain tumors, advanced neurosurgical infrastructure, and favorable reimbursement systems. The U.S. benefits from early adoption of technological advancements, such as the FDA-cleared Elekta Esprit platform, which enhances treatment precision and safety.   

India Gamma Knife Market

This rapid expansion is driven by a rising incidence of brain tumors and neurological disorders, growing medical tourism, and increased government and private sector investments in healthcare infrastructure.

Gamma Knife Market In China

China is one of the fastest-growing Gamma Knife markets globally, fueled by a large patient population, increasing healthcare spending, and rapid modernization of medical infrastructure. Chinese tertiary hospitals and cancer centers are increasingly adopting Gamma Knife systems, making advanced radiosurgery more accessible to a broader segment of the population.   

Market Report Scope

Gamma Knife Market: Growth Drivers

• Increasing inorganic growth activities such as acquisition by market players: 

Increasing inorganic growth activities such as acquisition by market players are expected to propel the growth of the global gamma knife market over the forecast period. For instance, in February 2021, Fujitsu Laboratories, Ltd., a technology equipment and services company, collaborated with researchers at the University of Toronto (U of T) for the development of a technology for dramatically streamlining the creation of radiation treatment plans for Gamma Knife radiosurgery. This leveraging Fujitsu’s quantum-inspired computing technology, the Digital Annealer, which rapidly solves combinatorial optimization problems.

Gamma Knife Market: Trends

• Increasing technological advancement: 

Increasing technological advancement by the market players is expected to drive the growth of the global gamma knife market over the forecast period. For instance, in August 16, 2023, GK Financing LLC (GKF), a subsidiary of American Shared Hospital Services, launched its new dedicated website, www.gkfinancingllc.com, which aims to revolutionize the way healthcare professionals in neuroscience and radiosurgery access creative financing alternatives to obtain the Gamma Knife for non-invasive radiosurgery treatments.

Gamma Knife Market: Opportunities

Technological advancements present another significant opportunity. Innovations in imaging, AI-assisted treatment planning, and robotic integration are enhancing the precision and safety of Gamma Knife procedures, making them more attractive to both providers and patients. Additionally, the expansion of healthcare infrastructure and rising medical expenditures in emerging economies particularly across Asia-Pacific are opening new markets, as more hospitals and cancer centres gain access to advanced radiosurgery systems.

Gamma Knife Market: Key Developments

• May 2025, KIMS Hospital has unveiled its cutting-edge Gamma Knife Center, bringing world-class, non-invasive brain treatment technology to Hyderabad. The newly launched facility is poised to transform the way complex brain disorders are treated, offering patients a safer, faster, and highly precise alternative to traditional brain surgery.
• June 2024, Fortis Memorial Research Institute proudly announces the launch of the South Asia's First Gamma Knife Esprit. This groundbreaking version of the Leksell Gamma Knife® heralds a new era in the non-surgical high precision treatment of brain tumours, greatly enhancing therapeutic options for both malignant, benign brain tumours and other abnormalities of Brain.

Analyst Opinion

• The global gamma knife market is poised for growth, due to advancement in technology, increasing prevelance of nuerological disorder, maximizing access to non-invasive treatment options.
• Asia Paciifc is expected to lead the global gamma knife market during the forecast period. This growth is attributed by rising neurological disorders and increaing healthcare spendings.
• Technological intergration such as Artificial intelligence and real time imaging has enhanced precision and efficieny.

Gamma Knife Market: Key Companies

Some of the key players in the global Gamma Knife market are Elekta, American Radiosurgery Inc., and Masep Medical Science & Technology Development Co., Ltd., Panacea Medical Technologies Pvt. Ltd., and Nordion (Canada) Inc.  

Market Segmentation

• Global Gamma Knife Market, By Indication:
  • Brain Metastasis
  • Arteriovenous Malformation (AVM)
  • Trigeminal Neuralgia
  • Others
• Global Gamma Knife Market, By Anatomy:
  • Head
  • Neck
  • Others
• Global Gamma Knife Market, By End User:
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
• Global Gamma Knife Market, By Region:
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Company Profiles
  • Elekta AB
  • American Radiosurgery Inc.
  • Masep Medical Science & Technology Development Co., Ltd.
  • Panacea Medical Technologies Pvt. Ltd.,
  • Nordion (Canada) Inc.  

Sources

Primary Research interviews:

• Neurosurgeons specializing in stereotactic radiosurgery
• Radiation oncologists
• Hospital procurement heads
• Department heads at cancer centers (e.g., Mayo Clinic, Cleveland Clinic, AIIMS)
• Medical physicists and radiology technicians
• Distributors of Elekta Gamma Knife systems
• Product managers at Elekta AB (key manufacturer)
• Health economists focused on oncology technology

Databases:

• WHO Global Health Observatory
• OECD Health Statistics
• NIH ClinicalTrials.gov (for Gamma Knife-related trials)
• PubMed/NCBI (for global treatment volumes & clinical efficacy data)
• GlobalData Healthcare Intelligence (if accessible through academic institutions)
• Medicare & Medicaid Services (CMS) reimbursement data

Magazines:

• Imaging Technology News (ITN)
• Radiology Business
• MedTech Dive
• DOTmed News
• HealthCare Business News

Journals:

• Journal of Neurosurgery
• Neurosurgery
• The Lancet Oncology
• Radiation Oncology (BioMed Central)
• Journal of Radiosurgery and SBRT
• Journal of Medical Physics
• Clinical Neurology and Neurosurgery
• Journal of Neuro-Oncology

Newspapers:

• The Wall Street Journal (Health and MedTech sections)
• The New York Times – Science & Health
• Financial Times – Healthcare Innovation
• The Economic Times – Healthcare and Devices (India)
• Nikkei Asia – Medtech and hospital investment in Asia

Associations:

• American Society for Radiation Oncology (ASTRO)
• International Stereotactic Radiosurgery Society (ISRS)
• National Cancer Institute (NCI)
• World Federation of Neurosurgical Societies (WFNS)
• Society of Neuro-Oncology (SNO)
• European Association of Neurosurgical Societies (EANS)
• US Food & Drug Administration (FDA)
• European Medicines Agency (EMA)

Proprietary Elements:

• CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 8 years

*Definition: Gamma knife is an advanced radiation therapy used for the treatment of cancer among adults and children of all ages. It is basically a beam of highly focused gamma rays used for precisely cutting or destroying tumors or damaged cells in the brain. Gamma knife uses tiny beams of radiation for the treatment of tumor and carcinogenic region of thre body. It is most often used in the treatment of neurological conditions such as brain metastases, acoustic neuroma and trigeminal neuralgia.